TScan Therapeutics (TCRX) announced the appointment of Stephen Camiolo as Senior Vice President, SVP, Market Access. Camiolo brings to TScan over 25 years of experience in market access, reimbursement, pricing strategy, sales, marketing, and account management across the pharmaceutical and biotechnology industries.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCRX:
- TScan Therapeutics assumed with an Overweight at Morgan Stanley
- TScan Therapeutics: Promising Advances in TCR-Engineered Cancer Therapies Justify Buy Rating
- Positive Buy Rating for TScan Therapeutics Driven by Promising Clinical Data and Strong Financial Position
- TScan Therapeutics price target lowered to $3 from $14 at Barclays
- Positive Outlook for TScan Therapeutics: Buy Rating Affirmed Due to Promising TCR-T Cell Therapy Progress and Solid Financial Position